We distribute our research widely to institutional and retail investors through various channels, including our proprietary database, website, and other platforms (such as Bloomberg, Refinitiv and Factset).

We are fully MiFID II compliant. Our research is paid for by our corporate clients, and we do not carry out any execution business.

Published reports can be obtained by searching our Research Library below, or directly from our Featured Companies page.

Advanced search
Date range (dd-mm-yyyy)

Avacta

Tumour-activated drug delivery demonstrated

Update | 07 July 2026

Oxford BioDynamics

H126: encouraging progress but challenges remain

Lighthouse | 01 July 2026

Scancell

iSCIB1+ pivotal trial plans advancing

Update | 22 June 2026

HUTCHMED

ATTC data confirms clinical potential

Update | 09 June 2026

Avacta

Raise of £9m pays down convertible bond to c £11.5m

Lighthouse | 08 June 2026

Avacta

FY25 results: clinical data will define the coming year

Lighthouse | 20 May 2026

Avacta

AVA6103 (FAP-Exd) starts Phase Ia FOCUS clinical trial

Update | 08 April 2026

Avacta

£10m raise extends runway beyond FAP-EXd catalysts

Lighthouse | 27 March 2026

HUTCHMED

Momentum in revenues, ATTC development promise

Lighthouse | 06 March 2026

Avacta

Innovative AI analysis comparing pre|CISION PDCs to ADCs

Lighthouse | 24 February 2026
1 2 3 4 5 6 7 8 9 10 >
507 results found.